Under the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab — developed and manufactured by Biocon Biologics — for an addressable market opportunity of USD 700 million, Biocon Biologics said in a statement.
English 
हिन्दी